Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
BackgroundAlthough immune checkpoint inhibitors (ICIs) generally show poor therapeutic efficacy in patients with epidermal growth factor receptor (EGFR) mutations, certain research indicate that a small proportion of these patients do respond to ICIs. The present study sought to identify the feature...
| প্রধান লেখক: | , , , , , , |
|---|---|
| বিন্যাস: | প্রবন্ধ |
| ভাষা: | English |
| প্রকাশিত: |
Frontiers Media S.A.
2022-08-01
|
| মালা: | Frontiers in Immunology |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.931718/full |